Microaneurysm (MA) turnover increases with the progression of nonproliferative diabetic retinopathy (NPDR) and is correlated with presence of intraretinal microvascular abnormalities (IRMAs), ...

The Sultanate of Oman is the third country worldwide to implement this project, confirming its commitment to technological ...

GLP-1 receptor agonists linked to modestly increased risk for incident DR, but tied to reduced risk for certain complications of DR.

Studies have linked GLP-1 medications to various eye conditions, some of which may lead to vision loss. Despite these findings, a clear link has yet to be established, and much of the evidence remains ...

This study is significant as it explores a potential new treatment option for diabetic retinopathy, a leading cause of blindness. The intervention tested was EYP-1901, a Tyrosine Kinase Inhibitor, ...

British number one blind golfer Billy McAllister recalls his journey in the sport after completely losing his eyesight in ...

Macular edema (ME), a leading cause of central vision loss, is often treated with anti-vascular endothelial growth factor ...

Macular edema (ME), a leading cause of central vision loss, is often treated with anti-vascular endothelial growth factor (anti-VEGF) injections ...

Historically, managing type 2 diabetes in advanced chronic kidney disease (CKD) has been challenging due to a lack of therapies and increased risks for adverse events.

Loss Drug to Irreversible Blindness A growing wave of lawsuits is targeting Novo Nordisk, the manufacturer of the widely used drugs Ozempic and Wegovy, following a recent study that suggests a link ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

The UC Davis team is studying a less invasive way of delivering gene therapy to the eye: injecting the gene therapy into the suprachoroidal space, a tiny layer between the white of the eye and the ...